Shed syndecan-1 inhibits myeloma cell growth: A mechanism of autocrine growth control in multiple myeloma.

被引：0
|
作者：
Dhodapkar, M
Theus, A
Langford, K
Butch, A
Barlogie, B
Sanderson, R
机构：
[1] UNIV ARKANSAS,LITTLE ROCK,AR 72204
[2] VAMC,LITTLE ROCK,AR
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [31] INTERLEUKIN-1 AUTOCRINE GROWTH SYSTEM IN HUMAN MULTIPLE-MYELOMA
    NAGATA, K
    TANAKA, Y
    ODA, S
    YAMASHITA, U
    ETO, S
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1991, 21 (01) : 22 - 29
  • [32] Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth
    Beauvais, DeannaLee M.
    Jung, Oisun
    Yang, Yang
    Sanderson, Ralph D.
    Rapraeger, Alan C.
    CANCER RESEARCH, 2016, 76 (17) : 4981 - 4993
  • [33] Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
    Mahtouk, Karene
    Hose, Dirk
    Reme, Thierry
    Hundemer, Michael
    Jourdan, Michel
    Jourdan, Eric
    Pantesco, Veronique
    Baudard, Marion
    De Vos, John
    Larroque, Marion
    Moehler, Thomas
    Rossi, Jean-Francois
    Goldschmidt, Hartmut
    Klein, Bernard
    BLOOD, 2006, 108 (11) : 999A - 999A
  • [34] Growth control mechanisms in multiple myeloma
    Hawley, RG
    Berger, LC
    LEUKEMIA & LYMPHOMA, 1998, 29 (5-6) : 465 - 475
  • [35] Binding of TACI and APRIL to syndecan-1 confer on them a major role in multiple myeloma
    Moreaux, J.
    Mahtouk, K.
    Hose, D.
    Moine, P.
    Robert, N.
    Baudard, M.
    Goldschmidt, H.
    Rossi, J. F.
    Klein, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 116 - 117
  • [36] Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival
    Andersen, NF
    Standal, T
    Nielsen, JL
    Heickendorff, L
    Borset, M
    Sorensen, FB
    Abildgaard, N
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (02) : 210 - 217
  • [37] Prognostic value of syndecan-1 in multiple myeloma and its relationship with other prognostic factors
    Kumar, S
    Blood, E
    Oken, MM
    Greipp, PR
    BLOOD, 2004, 104 (11) : 660A - 660A
  • [38] PK11195, a ligand of the peripheral benzodiazepine receptor, inhibits myeloma cell growth in vitro and chemosensitizes myeloma cells in vivo in SCID-hu models of human multiple myeloma.
    Campbell, Richard A.
    Sanchez, Eric
    Chen, Haiming
    Turker, Lauren
    Trac, Olivia
    Li, Mingjie
    Shalitin, Dror
    Gordon, Melinda S.
    Pang, Shen
    Bonavida, Benjamin
    Said, Jonathan
    Berenson, Ronald J.
    Berenson, James R.
    BLOOD, 2006, 108 (11) : 987A - 987A
  • [39] Human myeloma cells shed syndecan-1 in vitro:: Evidence for mediation by a non-matrix metallproteinase.
    Holen, I
    Dury, NL
    Hargreaves, PG
    Croucher, PI
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (06) : 1222 - 1222
  • [40] Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease
    Kyrtsonis, MC
    Vassilakopoulos, TP
    Siakantaris, MP
    Kokoris, SI
    Gribabis, DA
    Dimopoulou, MN
    Angelopoulou, MK
    Pangalis, GA
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (04) : 252 - 258
12345